Clinical review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)

The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of travoprost 0.003% PQ for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma(OAG)

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health September 2017, 2017
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of travoprost 0.003% PQ for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma(OAG)
Item Description:"Version: Final."
Physical Description:1 PDF file (48 pages) illustrations